Skip to main content

Table 2 Patient treatment patterns among the treatment-naïve propensity score-matched study population (N = 1,746)

From: Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort

Post-index treatment patterns Total Febuxostat Allopurinol Febuxostat vs. allopurinol
(N = 1,746) (N = 873) (N = 873) P value
  N % n % n %  
Prophylaxis treatment 940 53.8% 510 58.4% 430 49.3% <0.001
  Steroids 597 34.2% 323 37.0% 274 31.4% 0.013
  NSAIDs 362 20.7% 180 20.6% 182 20.9% 0.906
  Colchicines 354 20.3% 225 25.8% 129 14.8% <0.001
Index febuxostat dose        
  40 mg 726 41.6% 726 83.2% - - -
  80 mg 147 8.4% 147 16.8% - - -
Index allopurinol dose        
  100 mg 350 20.1% - - 350 40.1% -
  101-299 mg 129 7.4% - - 129 14.8% -
  300 mg 369 21.1% - - 369 42.3% -
  >300 mg 25 1.4% - - 25 2.9% -
Index medication dose change 458 26.2% 160 18.3% 298 34.1% <0.001
Percent of dose change        
  51-99% reduction 28 1.6% 0 0.0% 28 3.2% <0.001
  1-50% reduction 38 2.2% 6 0.7% 32 3.7% <0.001
  1-50% increase 46 2.6% 1 0.1% 45 5.2% <0.001
  51-100% increase 241 13.8% 143 16.4% 98 11.2% 0.002
  >100% increase 105 6.0% 10 1.2% 95 10.9% <0.001
  Mean SD Mean SD Mean SD  
Time to dose change (days) 198 197 211 188 192 202 0.32
Index medication dose immediately prior to sUA goal attainment of <6 mg/dl N/A N/A 54.1 20.5 275.8 109.5 N/A
Index medication dose immediately prior to sUA goal attainment of <5 mg/dl N/A N/A 55.0 21.5 302.0 125.8 N/A
  1. N/A, not applicable, since the dose for febuxostat and allopurinol are different and averaging of doses is meaningless. NSAIDs, nonsteroidal anti-inflammatory drugs; SD, standard deviation; sUA, serum urate.